guanosine-triphosphate and ARS-1620

guanosine-triphosphate has been researched along with ARS-1620* in 1 studies

Other Studies

1 other study(ies) available for guanosine-triphosphate and ARS-1620

Article	Year
Discovery of ARS-1620 analogs as KRas G12C inhibitors with high in vivo antitumor activity. Bioorganic chemistry, 2022, Volume: 121 KRas is the most frequently mutated protein of the three Ras isoforms in various cancer types. KRas mutations (i.e. G12C) are present in approximately 30% of human cancers. Based on our previously reported KRas G12C inhibitor LLK-10, we designed a series of quinazoline analogues with a trifluoromethacrylic acid warhead as covalent inhibitor of KRas G12C. The pharmacological activities of these compounds were assessed against a panel of KRas G12C mutated cancer cells (i.e. H358 and H23). Among them, K20 showed that highest antiproliferative potency with an average IC Topics: Animals; Guanosine Triphosphate; Humans; Mice; Mice, Nude; Mutation; Neoplasms; Piperazines; Proto-Oncogene Proteins p21(ras); Quinazolines	2022

Article

Year

Discovery of ARS-1620 analogs as KRas G12C inhibitors with high in vivo antitumor activity.

Bioorganic chemistry, 2022, Volume: 121

KRas is the most frequently mutated protein of the three Ras isoforms in various cancer types. KRas mutations (i.e. G12C) are present in approximately 30% of human cancers. Based on our previously reported KRas G12C inhibitor LLK-10, we designed a series of quinazoline analogues with a trifluoromethacrylic acid warhead as covalent inhibitor of KRas G12C. The pharmacological activities of these compounds were assessed against a panel of KRas G12C mutated cancer cells (i.e. H358 and H23). Among them, K20 showed that highest antiproliferative potency with an average IC

Topics: Animals; Guanosine Triphosphate; Humans; Mice; Mice, Nude; Mutation; Neoplasms; Piperazines; Proto-Oncogene Proteins p21(ras); Quinazolines

2022